Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BK1310 pentavalent vaccine in healthy infants
NCT03891758Phase 3Completed
- Sponsor
- Mitsubishi Tanabe Pharma
- Start
- Apr 2019
- Primary completion
- Sep 2019
- Modality
- Therapeutic Vaccines
- Countries
- 1
01
Overview
Phase 3, randomised, single-blind trial of MT-2355 in Tetanus, diphtheria, pertussis and 2 more (2 arms), sponsored by Mitsubishi Tanabe Pharma. Primary endpoints: Antibody Prevalence Rate Against Anti-PRP With 1 μg/mL or Higher, Antibody Prevalence Rate Against Diphtheria Toxin and 3 more. Started Apr 2019; status: completed.
02
Drugs
MT-2355
03
Conditions
Tetanusdiphtheriapertussispoliomyelitisbacterial meningitis
Beyond the preview
Go deeper on NCT03891758.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03891758.